Fasciola hepatica antioxidant and protease-inhibitor cocktail recombinant vaccines administered five times elicit potent and sustained immune responses in sheep but do not confer protection.

Autor: Cwiklinski K; Molecular Parasitology Laboratory, Centre for One Health and Ryan Institute, University of Galway, Galway, Ireland; Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, UK. Electronic address: krystyna.cwiklinski@liverpool.ac.uk., McEvoy A; Animal & Bioscience Department, Teagasc Mellows Campus, Athenry, Co., Galway, Ireland., López Corrales J; Molecular Parasitology Laboratory, Centre for One Health and Ryan Institute, University of Galway, Galway, Ireland., Jewhurst H; Molecular Parasitology Laboratory, Centre for One Health and Ryan Institute, University of Galway, Galway, Ireland., Calvani NED; Molecular Parasitology Laboratory, Centre for One Health and Ryan Institute, University of Galway, Galway, Ireland., De Marco Verissimo C; Molecular Parasitology Laboratory, Centre for One Health and Ryan Institute, University of Galway, Galway, Ireland., Dorey AL; Molecular Parasitology Laboratory, Centre for One Health and Ryan Institute, University of Galway, Galway, Ireland., Keane OM; Animal & Bioscience Department, Teagasc Grange, Dunsany, Co. Meath, Ireland., Dalton JP; Molecular Parasitology Laboratory, Centre for One Health and Ryan Institute, University of Galway, Galway, Ireland., Lalor R; Molecular Parasitology Laboratory, Centre for One Health and Ryan Institute, University of Galway, Galway, Ireland.
Jazyk: angličtina
Zdroj: Veterinary parasitology [Vet Parasitol] 2023 Nov; Vol. 323, pp. 110049. Date of Electronic Publication: 2023 Oct 08.
DOI: 10.1016/j.vetpar.2023.110049
Abstrakt: Our laboratory's vaccine development strategy against the livestock parasite Fasciola hepatica centres around disrupting key biological processes by combining groups of antigens with similar/complementary functional actions into a single vaccine cocktail. In this study the focus was on antioxidant protein vaccines and a protease inhibitor vaccine aimed at disrupting the parasite's ability to defend against oxidative stress and protease-inhibitor balance, respectively. Two combinations of recombinantly expressed antioxidants were assessed, namely peroxiredoxin (rFhPrx), thioredoxin (rFhTrx) and thioredoxin-glutathione reductase (rFhTGR) (Group 1) and rFhPrx, rFhTrx, and two superoxide dismutases (rFhSOD1 and rFhSOD3) (Group 2). The protease inhibitor vaccine cocktail included representatives of each of the key secreted protease inhibitor families, namely a Kunitz-type inhibitor (rFhKT1), a serpin (rFhSrp1) and a stefin, (rFhStf1) (Group 3). The vaccine combinations were formulated in adjuvant Montanide 61VG administered at five timepoints; two before experimental challenge with 60 F. hepatica metacercariae and three after infection. The vaccine combinations did not reduce the liver fluke burden, and only Group 2 displayed a marginal reduction in egg viability (8.2%). Despite previous results showing an effect of liver fluke vaccines on overall weight gain in infected animals, no significant (P value >0.05) impact on weight gain was observed in this study. Antibodies were elicited against all the vaccine antigens within the cocktails and were maintained at high levels to the end of the trial, due to our strategy of continuing vaccine administration after infection. However, these responses were not boosted by the challenge F. hepatica infection. A comparative analysis with previous vaccine data using a protease inhibitor vaccine found no repeat of the promising outcomes associated with this vaccine, indicating that the addition of rFhSrp1 to the vaccine cocktail did not improve vaccine efficacy. Assessment of liver pathology across the two trials using a modified liver enzyme score (glutamate dehydrogenase to platelet ratio) at eight weeks post infection suggests an association with liver fluke burden above 45 flukes, which could be used to predict liver pathology in future trials. The results reported in this study highlight the ambiguousness in liver fluke vaccine development and the difficulty in obtaining consistent and repeatable protection. This work stresses the need for repetition of trials and the use of sufficiently sized groups to assess vaccine efficacy with adequate statistical power.
Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: